How the 340B Rebate Pilot Affects Hospitals, Health Centers and Rural Entities

One framework for every entity type

Every covered entity in the pilot follows the same HRSA framework: buy at WAC through the 340B wholesaler account, submit to Beacon within 45 days, and get paid or denied within 10 days. Most approved plans apply to all covered entity types. GSK is the exception, leaving out ADAPs that already receive their 340B discount as a rebate. If you are new to the pilot, start with our explainer on HRSA's revised rebate model.

Hospitals: medical claims and purchasing accounts

The pilot covers physician- and clinic-administered drugs, not only pharmacy dispenses. For hospitals, that means sending medical claim data such as the claim line number, rendering physician, unit of measure and health plan.

Purchasing discipline matters too. HRSA says pilot drugs should be ordered only through the 340B wholesaler account, and rebates may not be requested on purchases made at a GPO or other discounted price. Hospitals with mixed-use inventory and split billing will need their accumulator logic to reflect that. We cover this in more detail in split billing, WAC purchasing and cash flow.

Two questions to settle now: can your TPA pull medical claims from your EHR, and does your purchasing setup keep pilot NDCs in the right account?

Health centers: Medicaid billing and sliding fees

Under the pilot, the upfront price for pilot drugs is WAC, but HRSA expects the real cost to be the 340B ceiling price once the rebate is paid. To support Medicaid billing and sliding-fee scales, each manufacturer must post a quarterly ceiling price file by NDC-11 on Beacon, which can feed pharmacy billing systems. HRSA suggests checking those files against 340B OPAIS and working with your state Medicaid agency on billing practice.

The question to settle now: where will your billing system get its acquisition cost for pilot NDCs after January 1?

Rural entities: smaller teams and patient access

The new workflow adds daily submissions, status tracking, denial follow-up and payment matching. For smaller 340B teams, that is hard to absorb without automation. HRSA's notice also says that if a manufacturer makes exceptions for certain covered entities, for example entities without a TPA, rural hospitals or health centers, it must communicate them to HRSA and to the affected entities.

Access is the other concern. Commenters on the notice warned that if chain pharmacies stop offering 340B pricing on pilot drugs, patients may have to travel farther, a problem they described as especially acute in rural communities. Contract pharmacy terms also vary by manufacturer. Boehringer Ingelheim's plan, for example, keeps its existing limit of one contract pharmacy within 40 miles.

The question to settle now: will your contract pharmacies keep filling pilot drugs, and who on your team will work denials?

Cash flow worries everyone

HRSA set the 10-day payment deadline to fall before standard wholesaler payment terms, so covered entities should not have to float WAC for long. Across our recurring webinars, cash flow and payment timing was the top concern in our live polls, chosen by more than 43% of respondents.

Where Aventi fits

Aventi works with grantees and non-grantees, as a primary TPA or alongside your current one. We integrate with Epic, Cerner, eClinicalWorks, athenahealth and other EHRs for medical claims, and we submit to Beacon daily.

For drugs included in the rebate pilot, Aventi uses a separate rebate pathway. We capture eligible claims only after the medication has been dispensed and picked up by the patient, submit them to Beacon and track each one to payment, so they stay out of regular 340B replenishment. Drugs outside the pilot continue through our regular accumulation and replenishment workflow.